Peer-influenced content. Sources you trust. No registration required. This is HCN.
Mayo Clinic Labs
Poor metabolizers of UGT1A1 face a significantly increased risk of severe neutropenia from irinotecan therapy, making genetic testing crucial for appropriate dose modification.
Clinical Pharmacology December 3rd 2024
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH